Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
05:53:19 EDT Tue 27 Oct 2026
Enter Symbol
or Name
USA
CA



Q:ATOS - ATOSSA THERAPEUTICS INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
ATOS - Q0.12.20·2.820.12.45-0.15-5.835.1712862.58  2.58  2.4014.85  1.70Oct 26Oct 1915 min RT 2¢

Recent Trades - Last 10 of 286
Time ETExPriceChangeVolume
     
     
     
     
     
     
     
     
     
     

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-10-19 08:00U:ATOSNews ReleaseAtossa Therapeutics Common Stock to Begin Trading with Stapled Contingent Value Rights After Close of Business Today
2026-10-09 08:00U:ATOSNews ReleaseAtossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation in Potential Priority Review Voucher Value
2026-09-29 08:00U:ATOSNews ReleaseAtossa Therapeutics Announces Plan to Issue Stapled CVR for Shareholders Tied to Potential Rare Pediatric Disease Priority Review Voucher
2026-09-24 08:00U:ATOSNews ReleaseAtossa Therapeutics CEO Dr. Steven Quay to Participate in ARDD 2026 Panel on Clinical Trials and Regulatory Pathways for Diseases of Aging
2026-08-07 08:45U:ATOSNews ReleaseAtossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
2026-07-28 08:30U:ATOSNews ReleaseAtossa Therapeutics Announces Publication of Novel (Z)-Endoxifen-Related Compounds Demonstrating Potent Anti-Cancer Activity in ER-Positive Breast Cancer
2026-07-21 08:30U:ATOSNews ReleaseAtossa Therapeutics Announces Presentation of Mechanism-Driven (Z)-Endoxifen Data in McCune-Albright Syndrome at AACR Special Conference on Rare Cancers
2026-06-12 17:30U:ATOSNews ReleaseAtossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds
2026-06-11 08:00U:ATOSNews ReleaseAtossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds
2026-05-27 08:30U:ATOSNews ReleaseAtossa Therapeutics Announces ASCO 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across ESR1 Mutations and Ongoing EVANGELINE Phase 2 Trial
2026-05-20 16:45U:ATOSNews ReleaseAtossa Therapeutics Announces Acceptance of Manuscript Highlighting Utrophin-Modulation Potential of (Z)-Endoxifen in Duchenne Muscular Dystrophy
2026-05-14 08:30U:ATOSNews ReleaseAtossa Therapeutics to Host Virtual KOL Event Featuring Dr. Laura Esserman to Discuss Development of (Z)-Endoxifen in ER-Positive Breast Cancer
2026-05-08 08:45U:ATOSNews ReleaseAtossa Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
2026-05-06 08:30U:ATOSNews ReleaseAtossa Therapeutics Announces Publication of KARISMA Endoxifen Trial Demonstrating Significant Reduction in Mammographic Breast Density in Healthy Premenopausal Women
2026-05-04 08:30U:ATOSNews ReleaseAtossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for McCune-Albright Syndrome
2026-03-25 17:30U:ATOSNews ReleaseAtossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update
2026-03-19 11:00U:ATOSNews ReleaseThe Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology
2026-03-19 08:00U:ATOSNews ReleaseAtossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two Experienced Biopharma Executives
2026-03-12 08:00U:ATOSNews ReleaseAtossa Therapeutics Presents Clinical Trial Update Highlighting (Z)-Endoxifen Research at the 2026 MDA Clinical & Scientific Conference
2026-02-11 08:30U:ATOSNews ReleaseAtossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 Outlook